Venture Investing
Investing in Solugen | How to Buy Pre-IPO Shares
Add Securities.io to your preferred sources on Google
Solugen is a private U.S. chemical-manufacturing company that combines engineered enzymes and conventional chemistry in its Bioforge process to make industrial chemicals from plant-derived feedstocks.
The latest company-confirmed priced equity round remains the more-than-$200 million Series D announced in 2022 at a valuation above $2 billion. A conditional federal loan guarantee is debt support, not equity funding.
What Is Solugen?
Founded in 2016, Solugen operates a Houston Bioforge and is developing additional manufacturing capacity and partnerships for water, energy, agriculture, cleaning, concrete, and other chemical markets.
Business Model and Key Products
The company’s technology can reduce fossil inputs and emissions, but industrial scale depends on feedstock economics, plant yields, utilization, customer qualification, construction, and continued access to capital.
Solugen Funding and Valuation History
Solugen states that it has raised more than $640 million. The reconciled chart groups approximately $83 million of earlier equity, more than $350 million Series C, and more than $200 million Series D; the conditional federal loan guarantee is excluded.
Solugen Selected Funding Events
Verified disclosed or aggregated equity financing, USD millions; debt and grants excluded.
Verified Aug. 29, 2026
Through 2022 · $0–$400M
| Date | Round / type | Funding Raised | Reported valuation | Selected investors | Source |
|---|---|---|---|---|---|
| Oct. 31, 2022 | Series D | More than $200M | More than $2B | Kinnevik; Lowercarbon; Refactor; Temasek; Baillie Gifford; others | Solugen |
| Sep. 2021 | Series C | More than $350M | About $1.8B | GIC; Baillie Gifford; Temasek; BlackRock; others | Solugen company history |
| Through 2020 | Earlier equity financing | More than $83M aggregate | Not disclosed | Fifty Years; Founders Fund; Y Combinator; others | Solugen company history |
| June 13, 2024 | Conditional loan guarantee | Up to $213.6M | Not applicable | U.S. Department of Energy Loan Programs Office | Solugen |
Methodology: The table follows Solugen’s own more-than-$640-million statement and groups the multiple early rounds. The conditional DOE loan guarantee, grants, customer contracts, and strategic project commitments are excluded from equity funding. This company should not be confused with the unrelated Canadian fertilizer business using a similar name.
Investment Case
The investment case depends on Solugen converting its product position into durable growth while managing execution, competition, financing, and private-market constraints.
Bioforge Process
Combining biology and chemistry could reduce energy use, emissions, and plant complexity.
Large End Markets
Industrial chemicals serve diverse, high-volume markets.
Commercial Partnerships
Established chemical and agriculture partners can provide feedstocks, customers, and scale.
Domestic Manufacturing
Policy and customer demand support resilient lower-carbon supply chains.
Key Risks
Scale-Up Risk
Laboratory and demonstration economics may not persist at commercial plant scale.
Project Capital
New plants require construction, commissioning, utilization, and working capital.
Commodity Competition
Petrochemical incumbents compete on cost, reliability, and established distribution.
Feedstock and Customer Qualification
Raw-material economics and lengthy product qualification can delay growth.
Valuation and Information Risk
The latest disclosed financing may be stale, and private-company financial information can be limited. The offered price may differ materially from both the last preferred round and current fundamentals.
Liquidity and Transaction Risk
Interests in Solugen may be scarce, restricted, difficult to resell, and offered through an SPV whose fees and rights differ from direct preferred shares.
How to Buy Solugen Pre-IPO Shares
- Confirm that Solugen remains private. Check for an SEC registration statement, a confirmed listing, or a material corporate transaction before pursuing private shares.
- Confirm your eligibility. Many late-stage secondary offerings use Regulation D and are limited to accredited investors. Individuals may qualify through net worth, income, or specified professional criteria.
- Find a live opportunity. Search registered private-market platforms or work with a qualified broker. A platform’s inclusion here does not mean it currently lists Solugen.
- Review the security and vehicle. Determine whether the offer provides direct company shares or an interest in an SPV. Review share class, liquidation preferences, voting rights, information rights, and the investment manager.
- Evaluate price and fees. Compare the offered price and implied valuation with the latest financing while accounting for platform fees, carried interest, SPV expenses, and security rights.
- Review transfer and exit restrictions. Examine company consent requirements, rights of first refusal, holding periods, and what happens if an IPO or acquisition never occurs.
Accredited-investor criteria: Under current SEC criteria, an individual may qualify through net worth above $1 million excluding the primary residence; income above $200,000 individually or $300,000 with a spouse or partner in each of the prior two years with a reasonable expectation of the same; or certain professional criteria. Review the SEC criteria.
Where to Buy Solugen Pre-IPO Shares
Availability on private marketplaces changes with seller supply, company transfer restrictions, jurisdiction, and investor eligibility. Always verify the live offering rather than assuming that Solugen shares are available.
MicroVentures
MicroVentures facilitates primary and secondary private-company offerings. Eligibility, minimums, fees, investment structure, and availability vary by offering; Regulation D opportunities are limited to accredited investors.
View Available Private-Market Opportunities
Solugen availability is not guaranteed. Review the specific offering documents before investing.
| Platform | Typical access model | What to verify |
|---|---|---|
| StartEngine Private | Late-stage private-company offerings | Current issuer availability, eligibility, minimum, fees, and vehicle structure |
| Forge Global | Private-company secondary marketplace and brokerage | Seller availability, accreditation, price, share class, and transaction costs |
| EquityZen | Private-company offerings that may use pooled vehicles | SPV terms, fees, minimum, economic rights, and transfer conditions |
| Rainmaker Securities | Broker-assisted private-company transactions | Security source, broker fees, settlement, and company approval |
| Hiive | Private-market bids, asks, and facilitated trades | Indicative versus executable pricing, fees, and transfer restrictions |
| EquityBee | Employee stock-option financing and related exposure | Contract structure, payoff terms, fees, and whether exposure is direct or indirect |
| Augment | Private-market transaction platform | Counterparty, price, share class, fees, and settlement terms |
Solugen Valuation and IPO Outlook
Solugen remains private. No later company-confirmed priced equity round was found after the 2022 Series D.
Investors should verify plant output, yield, utilization, contracted demand, unit economics, project financing, loan conditions, and current capitalization.
Investing in Solugen Pre-IPO Shares | Conclusion
Solugen offers differentiated exposure to low-carbon biomanufacturing and specialty chemicals.
The opportunity should be weighed against execution, competition, valuation, information, dilution, and liquidity risks. Investors should verify current operating data and underwrite the exact security rather than relying on an assumed IPO.
Explore other pre-IPO investment opportunities.
Primary and Supporting Sources
- Solugen Series D announcement
- Solugen company history and funding milestones
- Solugen company updates
Disclaimer: This article is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Private securities can result in the loss of the entire investment and may remain illiquid indefinitely. Company and marketplace availability can change without notice. Verify all terms in the applicable offering documents and consult qualified professional advisers where appropriate.
